To convert the meeting times to your local time Click Here
Industry Hall 2
The incorporation of PARP inhibitors (PARPi) into standard-of-care therapy has dramatically altered the treatment landscape for women diagnosed with ovarian cancer. Despite this progress, overall survival for this malignancy remains poor, and most patients will ultimately progress with, and succumb to, recurrent disease. Response to single-agent chemotherapy for patients with recurrent disease remains dismal; therefore, novel, more effective targeted therapies are needed for women with ovarian cancer. Mirvetuximab soravtansine is an antibody-drug conjugate comprising a FRα-binding antibody, cleavable linker, and the maytansinoid DM4, a potent tubulin-targeting agent that targets the folate receptor. Mirvetuximab has demonstrated promising clinical activity in patients with platinum-resistant and sensitive ovarian cancer as a single agent and in combination.